These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37691195)

  • 1. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
    Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
    Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
    Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
    Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
    Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
    Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
    Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
    Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P
    Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
    Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J
    Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
    Copland M; Hamilton A; Elrick LJ; Baird JW; Allan EK; Jordanides N; Barow M; Mountford JC; Holyoake TL
    Blood; 2006 Jun; 107(11):4532-9. PubMed ID: 16469872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.
    Kumar H; Chattopadhyay S; Das N; Shree S; Patel D; Mohapatra J; Gurjar A; Kushwaha S; Singh AK; Dubey S; Lata K; Kushwaha R; Mohammed R; Dastidar KG; Yadav N; Vishwakarma AL; Gayen JR; Bandyopadhyay S; Chatterjee A; Jain MR; Tripathi AK; Trivedi AK; Chattopadhyay N; Ramachandran R; Sanyal S
    Haematologica; 2020 Apr; 105(4):971-986. PubMed ID: 31371410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting survival pathways in chronic myeloid leukaemia stem cells.
    Sinclair A; Latif AL; Holyoake TL
    Br J Pharmacol; 2013 Aug; 169(8):1693-707. PubMed ID: 23517124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.